Related Pages for BIOCON
- Option Chain
- Straddle OC
- Max Pain
- Put Call Ratio
- Option Analytics
- Call OI vs Put OI
- Strike Flow
- Call OI Chg vs Put OI Chg
- Call Vol vs Put Vol
- Buildup & Unwinding
- Vega Divergence
- Multi Strike OI
- Multi Straddle Analysis
- Price vs OI
- Time Series Table
- Time Series Multi Chart
- Volatility Skew
- Premium Decay
- IV - HV
- IV Intraday
- Future Chain
- Future Intraday Analysis
- Technical
- Financials
- Chart
- About
No results found.
BIOCON
Related News - BIOCON
Biocon: Company Plans Analyst And Investor Meeting On September 4th
31 Aug 2026 08:58 PM
Biocon: Company Plans Analyst And Investor Meeting On September 4th
True North Looking To Sell Shares Worth Rs 700 Cr In Co - NDTV Profit ( Biocon )
28 Aug 2026 09:51 AM
True North Looking To Sell Shares Worth Rs 700 Cr In Co - NDTV Profit ( Biocon )
Biocon: Company Gets Approval For Pegfilgrastim Biosimilar From Japan's Health Ministry
25 Aug 2026 08:36 AM
Biocon: Company Gets Approval For Pegfilgrastim Biosimilar From Japan's Health Ministry
Biocon: Bernstein on Biocon Upgrades with Target Price of ₹326 as US FDA approval for Yesintek autoinjectors improves patient convenience and retention, though longer-term growth remains constrained by rising competition and faster adoption of IL-23 therapies.
19 Aug 2026 09:08 AM
Biocon: Bernstein on Biocon Upgrades with Target Price of ₹326 as US FDA approval for Yesintek autoinjectors improves patient convenience and retention, though longer-term growth remains constrained by rising competition and faster adoption of IL-23 therapies.
Biocon: Company Gets U.S. FDA Approval For Yesintek (Ustekinumab-KFCE) Single-Dose Autoinjector
18 Aug 2026 08:55 AM
Biocon: Company Gets U.S. FDA Approval For Yesintek (Ustekinumab-KFCE) Single-Dose Autoinjector
Biocon: HSBC on Biocon Maintains Buy with Target Price of ₹490 as 1Q biosimilars sales were stable at ~US$300mn with stronger sales expected in 2H and beyond, while successful execution of new biosimilar launches, profitability improvement and cash-flow generation remain key to the turnaround.
07 Aug 2026 08:57 AM
Biocon: HSBC on Biocon Maintains Buy with Target Price of ₹490 as 1Q biosimilars sales were stable at ~US$300mn with stronger sales expected in 2H and beyond, while successful execution of new biosimilar launches, profitability improvement and cash-flow generation remain key to the turnaround.
Biocon: Jefferies on Biocon Maintains Hold with Target Price of ₹410 as Q1 was weak across all three divisions and management views June quarter as the trough, expecting improvement in 2HFY27 through biosimilar scale-up and higher generic utilisation; FY27-29 EBITDA estimates were cut 1-5%.
07 Aug 2026 08:57 AM
Biocon: Jefferies on Biocon Maintains Hold with Target Price of ₹410 as Q1 was weak across all three divisions and management views June quarter as the trough, expecting improvement in 2HFY27 through biosimilar scale-up and higher generic utilisation; FY27-29 EBITDA estimates were cut 1-5%.
Biocon: Bernstein on Biocon Maintains Underperform with Target Price of ₹326 as Q1 revenue grew 10% and EBITDA 7%, but sales remained ~5% below estimates, with biosimilars up 16% YoY yet missing estimates by 6%; H2 improvement is expected but likely insufficient to justify current valuations.
07 Aug 2026 08:57 AM
Biocon: Bernstein on Biocon Maintains Underperform with Target Price of ₹326 as Q1 revenue grew 10% and EBITDA 7%, but sales remained ~5% below estimates, with biosimilars up 16% YoY yet missing estimates by 6%; H2 improvement is expected but likely insufficient to justify current valuations.
Biocon: Citi on Biocon Maintains Sell with Target Price of ₹360 as 1QFY27 missed expectations due to weaker research services and biosimilars, with revenue up 10% largely on currency benefits while biosimilar constant-currency growth was only 5% and EBITDA margin fell to 25.5% amid pricing pressure and competition.
07 Aug 2026 08:58 AM
Biocon: Citi on Biocon Maintains Sell with Target Price of ₹360 as 1QFY27 missed expectations due to weaker research services and biosimilars, with revenue up 10% largely on currency benefits while biosimilar constant-currency growth was only 5% and EBITDA margin fell to 25.5% amid pricing pressure and competition.
Biocon: Expects Syngene International To Perform Well Between October And March.
06 Aug 2026 01:56 PM
Biocon: Expects Syngene International To Perform Well Between October And March.
Biocon: Co. Anticipates Strong Start For Aflibercept Biosimilar With Existing Contracts, Projected Gradual Increase In Market Share, And Stronger Growth Expected In H2. - Concall Update
06 Aug 2026 10:30 AM
Biocon: Co. Anticipates Strong Start For Aflibercept Biosimilar With Existing Contracts, Projected Gradual Increase In Market Share, And Stronger Growth Expected In H2. - Concall Update
Biocon: GLP-1 Product Line Continues To Be A Major Growth Factor - Concall Update
06 Aug 2026 10:19 AM
Biocon: GLP-1 Product Line Continues To Be A Major Growth Factor - Concall Update
Biocon: Expands Its Global Manufacturing Network To Strengthen Regional Supply In France, Portugal, Slovenia, And Spain.
06 Aug 2026 10:11 AM
Biocon: Expands Its Global Manufacturing Network To Strengthen Regional Supply In France, Portugal, Slovenia, And Spain.
BIOCON: Q1 CONS NET PROFIT 1.41B RUPEES VS 314M (YOY)
05 Aug 2026 04:54 PM
BIOCON: Q1 CONS NET PROFIT 1.41B RUPEES VS 314M (YOY)
BIOCON: Q1 REVENUE 43.4B RUPEES VS 39.42B (YOY)
05 Aug 2026 04:54 PM
BIOCON: Q1 REVENUE 43.4B RUPEES VS 39.42B (YOY)
BIOCON: Q1 EBITDA 8.5B RUPEES VS 7.49B (YOY) || Q1 EBITDA MARGIN 19.54% VS 19% (YOY)
05 Aug 2026 04:54 PM
BIOCON: Q1 EBITDA 8.5B RUPEES VS 7.49B (YOY) || Q1 EBITDA MARGIN 19.54% VS 19% (YOY)
Biocon: Company Gets Health Canada Approval For Yesintak Ustekinumab Autoinjector Pen To Treat Autoimmune Diseases.
29 Jul 2026 08:34 AM
Biocon: Company Gets Health Canada Approval For Yesintak Ustekinumab Autoinjector Pen To Treat Autoimmune Diseases.
Biocon: Biocon Malaysia Gets EMA Approval For New Insulin Drug Production Unit
16 Jul 2026 08:51 AM
Biocon: Biocon Malaysia Gets EMA Approval For New Insulin Drug Production Unit
Biocon: Bernstein on Biocon Maintains Underperform with Target Price of ₹326 as Viatris’ block deal exit does not change Biocon’s earnings outlook, citing high leverage, slow monetization of Biologics and Syngene investments, rising biosimilar competition due to policy changes, and succession concerns, with the $2 billion revenue milestone likely 4–5 years away.
15 Jul 2026 09:01 AM
Biocon: Bernstein on Biocon Maintains Underperform with Target Price of ₹326 as Viatris’ block deal exit does not change Biocon’s earnings outlook, citing high leverage, slow monetization of Biologics and Syngene investments, rising biosimilar competition due to policy changes, and succession concerns, with the $2 billion revenue milestone likely 4–5 years away.
Biocon: DAM Capital on Biocon Maintains Buy with Target Price of ₹495 as Mylan’s exit removes a long-standing overhang, while the biosimilars business has turned the corner with H2FY27 growth expected from bUstekinumab, bAspart, bDenosumab and bAflibercept launches, supporting a 15% FY26–28 revenue CAGR and 26–27% EBITDA margins.
15 Jul 2026 09:01 AM
Biocon: DAM Capital on Biocon Maintains Buy with Target Price of ₹495 as Mylan’s exit removes a long-standing overhang, while the biosimilars business has turned the corner with H2FY27 growth expected from bUstekinumab, bAspart, bDenosumab and bAflibercept launches, supporting a 15% FY26–28 revenue CAGR and 26–27% EBITDA margins.
